AstraZeneca PLC (AZNCF)

136.700
+2.920(+2.18%)
  • Volume:
    5,298
  • Bid/Ask:
    0.000/0.000
  • Day's Range:
    133.440 - 137.850
Unusual trading volume

AstraZeneca PLC has doubled (or more) its daily average of shares traded over the last 3 months. High volumes usually indicate new trends and larger share price movements.

AZNCF Overview

Prev. Close
133.78
Day's Range
133.44-137.85
Revenue
44.35B
Open
137.85
52 wk Range
104.5-144.5
EPS
2.12
Volume
5,298
Market Cap
210.01B
Dividend (Yield)
N/A
(N/A)
Average Volume (3m)
2,016
P/E Ratio
63.80
Beta
0.174
1-Year Change
2.08%
Shares Outstanding
1,549,841,278
Next Earnings Date
Apr 28, 2023
What is your sentiment on AstraZeneca PLC?
or
Market is currently closed. Voting is open during market hours.

AstraZeneca PLC Company Profile

AstraZeneca PLC Company Profile

Employees
83500

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company’s marketed products include Calquence, Enhertu, Faslodex, Imfinzi, Iressa, Koselugo, Lumoxiti, Lynparza, Orpathys, Tagrisso, and Zoladex for oncology; Andexxa/Ondexxya, Atacand, Atacand HCT, Atacand Plus, Brilinta/Brilique, Bydureon/Byetta, BCise, Byetta, Crestor, Evrenzo, Farxiga/Forxiga, Komboglyze/Kombiglyze XR, Lokelma, Onglyza, Qtern, Xigduo/Xigduo, and Zestril XR for cardiovascular, renal, and metabolism diseases; Accolate, Accoleit, Vanticon, Bevespi Aerosphere, Breztri Aerosphere, Bricanyl Respules and Turbuhaler, Daliresp/Daxas, Duaklir Genuair, Fasenra, Pulmicort, Rhinocort, Saphnelo, Symbicort, and Tezspire for respiratory and immunology; and Kanuma, Soliris, Strensiq, and Ultomiris for rare diseases. Its marketed products also comprise Synagis for respiratory syncytial virus; Fluenz Tetra/FluMist Quadrivalent for Influenza; and Vaxzevria and Evusheld for covid-19. The company serves primary care and specialty care physicians through distributors and local representative offices in the United Kingdom, rest of Europe, the Americas, Asia, Africa, and Australasia. It has a collaboration agreement with Neurimmune AG to develop and commercialize NI006; and Personalis, Inc. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.

Read More

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesStrong BuyStrong BuyStrong BuyStrong BuyStrong Buy
Technical IndicatorsStrong BuyStrong BuyStrong BuyStrong BuyStrong Buy
SummaryStrong BuyStrong BuyStrong BuyStrong BuyStrong Buy
  • Double top in reach
    0